

AVAC's Top Recommendations for 2010 and Beyond

We hope you'll turn all the pages of this Report—but here's a quick look at some of the critical messages we hope will guide the next chapter of HIV prevention research.



The biomedical HIV prevention field needs to respond to the contraction of global resources for HIV with clear messages, stringent priority setting and well-articulated plans for pursuing leads suggested by trials like RV144 as well as wholly novel lines of inquiry.



Global stakeholders—donors, governments, research sponsors and civil society—need to develop and fully fund an ambitious agenda aimed at sustaining and expanding ARV treatment for HIV-positive people, exploring treatment as prevention strategies *and* preparing for delivery of ARV-based prevention in HIV-negative people.



Build systems for sharing data and consensus on a core set of assays to be used to evaluate candidates to ensure that the AIDS vaccine field optimizes the data gleaned from every trial.



Complex trial designs require complex, long-term, multi-layered community engagement strategies. Investment in this work has to be upfront, not an afterthought, as ambitious plans for adaptive designs and other novel concepts are discussed by the scientific community.



To stay up-to-date with developments in these recommendations and many other issues, subscribe to AVAC's Advocates' Network www.avac.org/advocatesnetwork.